Floatz logo

hcw9218

Advanced Pancreatic Carcinoma

ImmunityBio, Inc.Phase 1/2Active
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

103 Active assets in the Advanced Pancreatic Carcinoma cohort.

Asset / SponsorPhaseRating
Irinotecan
OHSU Knight Cancer Institute
Phase 2/3BBB
FLUOROURACILUM
Northwestern University
Phase 2/3BBB
Eloxatin
OHSU Knight Cancer Institute
Phase 2/3BBB
Capecitabine
Zhejiang University
Phase 2BB
Gdc-0449
OHSU Knight Cancer Institute
Phase 2BB

View all 50 →

Same molecule, other indications

hcw9218 is also rated in:

ovarian cancerDormant
CC
Indicative ·
46 / 100
View asset →
neoplasmDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →